Trials / Unknown
UnknownNCT00633165
Brostallicin Clinical Trial for Myxoid Liposarcoma
A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Systems Medicine LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of Brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation. The primary objective of this study is to determine the response rate following Brostallicin administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brostallicin | Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-10-01
- Completion
- 2010-06-01
- First posted
- 2008-03-11
- Last updated
- 2010-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00633165. Inclusion in this directory is not an endorsement.